Syneos Health Expands Partnership with Datavant to Accelerate Delivery of New Therapies to Patients

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for Clients

MORRISVILLE, N.C., Oct. 11, 2022 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced an expanded partnership with Datavant, the leader in helping organizations securely connect health data. The increasing collaboration between the companies will further leverage the full suite of capabilities in Datavant Switchboard and Datavant’s large data ecosystem to accelerate the clinical development and commercialization of new therapies for patients.

Syneos Health and Datavant have a long-standing strategic partnership, and through this expanded relationship, Syneos Health will use Datavant Switchboard to develop advanced analytics and AI-driven technologies to execute more efficient clinical trials, creating an improved experience for patients, sites and biopharmaceutical customers. Additionally, the relationship empowers HEOR, Medical Affairs, Market Access and Commercialization analytics and insights to drive better analysis for Syneos Health’s biopharmaceutical customers’ products.

“Our continuous collaboration with Datavant will deliver to our customers an established clinical trial tokenization capability and the ability for our teams to leverage this approach to develop new, innovative solutions for conducting clinical research and driving product commercialization that is powered by data-driven insights,” said Bob Zambon, Vice President, Solution Design, Syneos Health. “We’re excited by the opportunity to further utilize the growing suite of capabilities in Datavant Switchboard to support our clients and sites in accelerating and diversifying their clinical trials.”

“Syneos Health has been a long-time strategic partner to Datavant in bringing trial tokenization to the industry,” said Tal Rosenberg, President and Chief Partnerships Officer. “Biopharma clients need access to better data and analytics as drug development becomes more precise and challenging. We are excited to expand our work with Syneos Health to enable them to build an enterprise data and analytics platform that leverages a robust ecosystem of data partners while also maintaining the highest standards for compliant, secure data exchange.”

This expanded collaboration also strengthens Syneos Health’s Medical Affairs position as a strategic partner for clients, bolstering the ability to bring Medical Affairs solutions into the broader clinical lifecycle and setting the stage for effective commercialization. The relationship underscores the importance of evidence continuity across various sources, including late phase studies, real world data sources for clinical development, health economics and outcomes research, and commercial analytics. This continuity across the product lifecycle is key to an integrated evidence generation plan that considers the patient voice, ultimately optimizing the trajectory of product launch and success. Additionally, the relationship includes access to Privacy Hub by Datavant, an industry-leading, independent patient-data disclosure risk assessment and expert determination, to enable the development of compliant linked datasets with the speed and quality required by innovative healthcare companies.

Datavant is also part of the Syneos Health Dynamic Assembly® Network, an open ecosystem of best-of-breed data and technology collaborators designed to strategically address the nuances of unique customer engagements, providing an “always on” innovation environment.

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically integrating clinical development, medical affairs and commercial capabilities to address modern market realities.

We bring together more than 29,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

About Datavant

Datavant’s mission is to connect the world’s health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building technology that protects the privacy of patients while supporting the linkage of patient health records across datasets. Learn more about Datavant at www.datavant.com.

Syneos Investor Relations Contact: Syneos Press/Media Contact:
Ronnie Speight Gary Gatyas
Senior Vice President, Investor Relations Executive Director, External Communications
+1 919 745 2745 +1 908 763 3428
Investor.Relations@syneoshealth.com gary.gatyas@syneoshealth.com
   
Datavant Media Contact:  
Larine Hamied  
Partner Marketing Lead  
larine@datavant.com  

Staff

Recent Posts

Eyemart Express Teams Up with “The Jennifer Hudson Show” to Encourage Young Readers

Partnership launches a summer digital series that celebrates the joy of reading DALLAS, June 24,…

1 hour ago

ZEISS Solves Industry Challenges at Tech Days Event

ZEISS Industry Tech Days brings together manufacturers across five states to show how advanced metrology…

1 hour ago

A Glimpse Into the Future of Mass Spectrometry: Game-Changing Technologies and Transformative Trends Unveiled at ASMS 2025

ARLINGTON, Va., June 24, 2025 /PRNewswire/ -- Behind the doors of the ASMS 2025 conference, held…

1 hour ago

Circulogene Launches LungLifeAI® Nationally Through Primary Care Channel

PENSACOLA, Fla., June 24, 2025 /PRNewswire/ -- Circulogene, a leading provider of precision diagnostics for…

1 hour ago

LevelJump Announces Revocation of Cease Trade Order; Seeking Reinstatement of Trading On TSX Venture Exchange

Toronto, Ontario--(Newsfile Corp. - June 24, 2025) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") is…

5 hours ago

AllianceHCM Appoints Alan Primeaux as Chief Executive Officer to Propel Next Phase of Growth

HOUSTON, June 24, 2025 /PRNewswire/ -- AllianceHCM, one of the nation's leading privately held providers…

7 hours ago